| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.33B | 9.92 | 70.86 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 720.1M | 4.25 | 11.18 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 881.27M | 2.22 | -1.73 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 572.64M | 7.30 | -2.38 | -117.82% | 0.18 | |||
| NKTRNektar Therapeutics | 719.28M | 35.36 | -4.07 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IMNMImmunome, Inc. | 2.52B | 22.85 | -4.57 | -35.5% | -23.01% | -84.4% | 0.03 | |
| IBRXImmunityBio, Inc. | 3.89B | 3.95 | -6.37 | 22.71% | -422.28% | |||
| NRIXNurix Therapeutics, Inc. | 1.91B | 18.86 | -6.55 | -29.15% | -292.5% | -65.76% | 0.05 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 55.04M | 42.58M | 25.19M | 12.73M | 15.19M | 51.06M | 30.35M | 19.17M | 755K | 41.51M |
| Revenue Growth % | 1.09% | -0.23% | -0.41% | -0.49% | 0.19% | 2.36% | -0.41% | -0.37% | -0.96% | 53.97% |
| Cost of Goods Sold | 2.71M | 1.69M | 2.62M | 2.74M | 11.39M | 1.95M | 1.84M | 8.48M | 7.42M | 9.18M |
| COGS % of Revenue | 0.05% | 0.04% | 0.1% | 0.22% | 0.75% | 0.04% | 0.06% | 0.44% | 9.83% | 0.22% |
| Gross Profit | 52.34M | 40.9M | 22.57M | 9.99M | 3.8M | 49.11M | 28.5M | 10.69M | -6.66M | 32.32M |
| Gross Margin % | 0.95% | 0.96% | 0.9% | 0.78% | 0.25% | 0.96% | 0.94% | 0.56% | -8.83% | 0.78% |
| Gross Profit Growth % | 1.31% | -0.22% | -0.45% | -0.56% | -0.62% | 11.93% | -0.42% | -0.63% | -1.62% | 5.85% |
| Operating Expenses | 82.87M | 104.86M | 115.22M | 115.08M | 127.35M | 91.42M | 131.98M | 100.35M | 90.64M | 91.88M |
| OpEx % of Revenue | 1.51% | 2.46% | 4.57% | 9.04% | 8.38% | 1.79% | 4.35% | 5.23% | 120.05% | 2.21% |
| Selling, General & Admin | 29.78M | 41.26M | 44.75M | 47.25M | 43.02M | 22.51M | 22.88M | 8.89M | 8.12M | 8.42M |
| SG&A % of Revenue | 0.54% | 0.97% | 1.78% | 3.71% | 2.83% | 0.44% | 0.75% | 0.46% | 10.75% | 0.2% |
| Research & Development | 57.3M | 74.56M | 79.23M | 76.57M | 92.04M | 77.05M | 117.84M | 97.5M | 87.65M | 90.54M |
| R&D % of Revenue | 1.04% | 1.75% | 3.15% | 6.01% | 6.06% | 1.51% | 3.88% | 5.09% | 116.09% | 2.18% |
| Other Operating Expenses | -10.88M | -19.38M | -17.9M | -25.42M | -7.71M | -8.14M | -8.74M | -6.04M | -5.13M | -7.08M |
| Operating Income | -30.53M | -63.96M | -92.65M | -105.09M | -123.55M | -42.31M | -103.48M | -89.67M | -97.3M | -59.55M |
| Operating Margin % | -0.55% | -1.5% | -3.68% | -8.25% | -8.13% | -0.83% | -3.41% | -4.68% | -128.88% | -1.43% |
| Operating Income Growth % | -3.79% | -1.1% | -0.45% | -0.13% | -0.18% | 0.66% | -1.45% | 0.13% | -0.09% | 0.39% |
| EBITDA | -28.62M | -61.75M | -89.28M | -102.71M | -116.68M | -34.48M | -89.33M | -71.23M | -78.78M | -39.71M |
| EBITDA Margin % | -0.52% | -1.45% | -3.54% | -8.07% | -7.68% | -0.68% | -2.94% | -3.72% | -104.34% | -0.96% |
| EBITDA Growth % | -5.08% | -1.16% | -0.45% | -0.15% | -0.14% | 0.7% | -1.59% | 0.2% | -0.11% | 0.5% |
| D&A (Non-Cash Add-back) | 1.91M | 2.21M | 3.37M | 2.38M | 6.88M | 7.83M | 14.16M | 18.43M | 18.52M | 19.85M |
| EBIT | -28.15M | -67.25M | -103.68M | -88.29M | -112.61M | -51.17M | -92.58M | -94.81M | -111.16M | -29.31M |
| Net Interest Income | 1.13M | -583K | 1.41M | 6.06M | 4.02M | -680K | -3.65M | -2.67M | -1.69M | 3.83M |
| Interest Income | 8.25M | 44.17K | 1.97M | 6.79M | 6.98M | 1.95M | 719K | 1.12M | 3.61M | 11.28M |
| Interest Expense | 22.96K | 6.31K | 560K | 723K | 2.96M | 12.05M | 4.37M | 3.79M | 5.31M | 7.45M |
| Other Income/Expense | 8.38M | 47K | -11.03M | 16.76M | 8.34M | -11.27M | 6.73M | -8.94M | -19.16M | 22.79M |
| Pretax Income | -22.27M | -63.92M | -103.68M | -88.33M | -115.21M | -53.58M | -96.75M | -98.6M | -116.46M | -36.76M |
| Pretax Margin % | -0.4% | -1.5% | -4.12% | -6.94% | -7.58% | -1.05% | -3.19% | -5.14% | -154.26% | -0.89% |
| Income Tax | -926.03K | -1.54M | -13.2M | 0 | 0 | 0 | -3K | 87K | 371K | 0 |
| Effective Tax Rate % | 1.01% | 1% | 0.96% | 0.89% | 0.89% | 1.51% | 1.18% | 1.08% | 0.87% | 1% |
| Net Income | -22.46M | -63.92M | -99.37M | -78.69M | -102.09M | -81.07M | -114.2M | -106.14M | -101.06M | -36.76M |
| Net Margin % | -0.41% | -1.5% | -3.95% | -6.18% | -6.72% | -1.59% | -3.76% | -5.54% | -133.85% | -0.89% |
| Net Income Growth % | -924.55% | -1.85% | -0.55% | 0.21% | -0.3% | 0.21% | -0.41% | 0.07% | 0.05% | 0.64% |
| Net Income (Continuing) | -22.61M | -67.25M | -103.68M | -88.33M | -115.21M | -53.58M | -96.75M | -98.69M | -116.83M | -36.76M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | -43.9M | -28.36M | -15.35M | 8.39M | 0 |
| Minority Interest | 792.64K | 1.87M | 19.11M | 40.97M | 40.35M | 25.05M | 15.18M | 7.97M | 0 | 0 |
| EPS (Diluted) | -0.65 | -1.78 | -2.78 | -1.93 | -2.14 | -1.71 | -1.93 | -2.33 | -1.77 | -0.41 |
| EPS Growth % | - | -1.74% | -0.56% | 0.31% | -0.11% | 0.2% | -0.13% | -0.21% | 0.24% | 0.77% |
| EPS (Basic) | -0.66 | -1.81 | -2.78 | -1.93 | -2.14 | -1.71 | -1.93 | -2.33 | -1.77 | -0.41 |
| Diluted Shares Outstanding | 34.52M | 35.81M | 35.69M | 40.77M | 42.44M | 42.5M | 44.82M | 45.55M | 57.01M | 90.57M |
| Basic Shares Outstanding | 34.15M | 35.29M | 35.69M | 40.77M | 42.44M | 42.5M | 44.82M | 45.55M | 57.01M | 90.57M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 365.4M | 311.79M | 323.22M | 487.64M | 391.52M | 315.36M | 225.43M | 143.81M | 233.01M | 287.07M |
| Cash & Short-Term Investments | 343.56M | 290.5M | 296.98M | 451.89M | 360.91M | 268.24M | 186.13M | 97.7M | 203.81M | 260.31M |
| Cash Only | 343.56M | 290.5M | 296.98M | 451.89M | 360.91M | 241.15M | 185.64M | 89.79M | 136.71M | 143.25M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 27.09M | 499K | 7.91M | 67.11M | 117.06M |
| Accounts Receivable | 16.55M | 3.63M | 4.57M | 22.07M | 15.29M | 19.19M | 31.07M | 17.57M | 23.13M | 23.04M |
| Days Sales Outstanding | 109.74 | 31.09 | 66.15 | 632.66 | 367.48 | 137.22 | 373.74 | 334.59 | 11.18K | 202.59 |
| Inventory | 172.74K | 117.79K | 250K | 275K | 2.9M | 1.61M | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 23.3 | 25.47 | 34.83 | 36.65 | 92.82 | 300.46 | - | - | - | - |
| Other Current Assets | 14.97M | 363K | 2.99M | 2.42M | 594K | 12.21M | 50K | 22.31M | 345K | 298K |
| Total Non-Current Assets | 7.48M | 18.89M | 9.66M | 13.2M | 75.95M | 154.11M | 156.65M | 117.41M | 101.27M | 96.48M |
| Property, Plant & Equipment | 5.51M | 16.86M | 7.23M | 10.04M | 69.32M | 145.52M | 148.27M | 107.9M | 92.74M | 75.86M |
| Fixed Asset Turnover | 9.98x | 2.53x | 3.49x | 1.27x | 0.22x | 0.35x | 0.20x | 0.18x | 0.01x | 0.55x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.05M | 1.34M | 1.43M | 1.27M | 1.11M | 1.58M | 1.85M | 718K | 672K | 1.11M |
| Long-Term Investments | 923.84K | 689.92K | 1M | 1.89M | 5.52M | 7.01M | 6.52M | 8.79M | 7.85M | 7.52M |
| Other Non-Current Assets | 1.09K | 0 | 102K | -1K | 5.52M | -1K | 3K | 0 | -1K | 11.6M |
| Total Assets | 372.88M | 330.68M | 332.88M | 500.84M | 467.47M | 469.47M | 382.08M | 261.22M | 334.27M | 383.54M |
| Asset Turnover | 0.15x | 0.13x | 0.08x | 0.03x | 0.03x | 0.11x | 0.08x | 0.07x | 0.00x | 0.11x |
| Asset Growth % | 1.23% | -0.11% | 0.01% | 0.5% | -0.07% | 0% | -0.19% | -0.32% | 0.28% | 0.15% |
| Total Current Liabilities | 84.12M | 56.04M | 43.53M | 46.87M | 62.6M | 52.02M | 49.35M | 62.99M | 155.14M | 166.27M |
| Accounts Payable | 7.23M | 9.72M | 9.46M | 15.88M | 29.26M | 24.61M | 23.76M | 21.46M | 19.07M | 18.66M |
| Days Payables Outstanding | 974.96 | 2.1K | 1.32K | 2.12K | 937.62 | 4.6K | 4.7K | 923.08 | 938.16 | 741.93 |
| Short-Term Debt | 66K | 1.69M | 0 | 0 | 0 | 0 | 2.25M | 4.97M | 5.16M | 4.84M |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 1000K | 452K | 301K | 59K | 1000K | 1000K |
| Other Current Liabilities | 10.19M | 1.46M | 2.02M | 2.86M | 4.95M | 7.21M | 2.16M | 16.16M | 2.72M | 13.37M |
| Current Ratio | 4.34x | 5.56x | 7.42x | 10.40x | 6.25x | 6.06x | 4.57x | 2.28x | 1.50x | 1.73x |
| Quick Ratio | 4.34x | 5.56x | 7.42x | 10.40x | 6.21x | 6.03x | 4.57x | 2.28x | 1.50x | 1.73x |
| Cash Conversion Cycle | -841.91 | -2.05K | -1.22K | -1.45K | -477.32 | -4.17K | - | - | - | - |
| Total Non-Current Liabilities | 549.93K | 588.95K | 3.44M | 3.7M | 49.4M | 108.61M | 96.25M | 72.28M | 94.43M | 95.25M |
| Long-Term Debt | 2.19K | 0 | 0 | 0 | 0 | 24.22M | 18.77M | 13.57M | 28.44M | 43.99M |
| Capital Lease Obligations | 69.97K | 30K | 13K | 1.02M | 46.54M | 75.76M | 71.53M | 49.36M | 42.95M | 34.24M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 158K | 0 |
| Other Non-Current Liabilities | 474.25K | 560K | 3.43M | 2.68M | 2.85M | 8.63M | 5.96M | 9.35M | 22.88M | 17.02M |
| Total Liabilities | 84.67M | 56.63M | 46.98M | 50.57M | 112M | 160.63M | 145.6M | 135.28M | 249.57M | 252.51M |
| Total Debt | 2.17M | 1.76M | 34K | 1.35M | 47.61M | 106.68M | 100.87M | 75.77M | 85.06M | 91.46M |
| Net Debt | -341.38M | -288.74M | -296.95M | -450.54M | -313.3M | -134.47M | -84.77M | -14.02M | -51.65M | -51.79M |
| Debt / Equity | 0.01x | 0.01x | 0.00x | 0.00x | 0.13x | 0.35x | 0.43x | 0.60x | 1.00x | 0.70x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -1329.73x | -10136.33x | -165.45x | -145.35x | -41.75x | -3.51x | -23.69x | -23.68x | -18.33x | -7.99x |
| Total Equity | 288.22M | 274.05M | 285.9M | 450.27M | 355.47M | 308.85M | 236.47M | 125.94M | 84.69M | 131.03M |
| Equity Growth % | 2.98% | -0.05% | 0.04% | 0.57% | -0.21% | -0.13% | -0.23% | -0.47% | -0.33% | 0.55% |
| Book Value per Share | 8.35 | 7.65 | 8.01 | 11.04 | 8.38 | 7.27 | 5.28 | 2.76 | 1.49 | 1.45 |
| Total Shareholders' Equity | 287.42M | 272.18M | 266.79M | 409.3M | 315.12M | 283.8M | 221.29M | 117.97M | 84.69M | 131.03M |
| Common Stock | 1.92M | 1.86M | 2.37M | 2.77M | 2.77M | 2.79M | 2.94M | 2.96M | 4.37M | 5.89M |
| Retained Earnings | -172.45M | -229.77M | -351.3M | -405.32M | -508.48M | -587.03M | -698.33M | -439.5M | -405.77M | -329.61M |
| Treasury Stock | -201.17K | -416K | -297K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.78M | 2.63M | 1.98M | -16.67M | -22.64M | -4.09M | -18.02M | -28.61M | -36.69M | -39.54M |
| Minority Interest | 792.64K | 1.87M | 19.11M | 40.97M | 40.35M | 25.05M | 15.18M | 7.97M | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 3.54M | -31.09M | -52.33M | -68.14M | -69.14M | -80.26M | -104.56M | -87.44M | -24.75M | 22.1M |
| Operating CF Margin % | 0.06% | -0.73% | -2.08% | -5.35% | -4.55% | -1.57% | -3.45% | -4.56% | -32.78% | 0.53% |
| Operating CF Growth % | -0.93% | -9.79% | -0.68% | -0.3% | -0.01% | -0.16% | -0.3% | 0.16% | 0.72% | 1.89% |
| Net Income | -22.27M | -63.92M | -103.68M | -88.33M | -115.21M | -53.58M | -96.75M | -98.69M | -116.83M | -36.7M |
| Depreciation & Amortization | 1.91M | 2.1M | 3.37M | 2.38M | 6.88M | 7.83M | 14.16M | 18.43M | 18.52M | 19.84M |
| Stock-Based Compensation | 32.91M | 55.71M | 50.42M | 37.22M | 26.88M | 10.03M | 11.49M | 6.04M | 5.23M | 0 |
| Deferred Taxes | 0 | 1.32M | 4.32M | 6.46M | 0 | 0 | 0 | 87K | 371K | 0 |
| Other Non-Cash Items | -7.49M | -1.4M | 11.04M | -16.76M | 661K | -27.22M | -21.16M | -7.6M | 71.95M | -14.61M |
| Working Capital Changes | -1.52M | -24.9M | -17.79M | -9.1M | 11.65M | -17.32M | -12.3M | -5.72M | -3.99M | 53.57M |
| Change in Receivables | 1.25M | -947.58K | -549K | -3.7M | 4.68M | -3.23M | -12.44M | -8.99M | 2.25M | -6.72M |
| Change in Inventory | -25.15K | 47.33K | -109K | -37K | -2.63M | 100K | 215K | 0 | 0 | 0 |
| Change in Payables | 2.92M | -4.17M | -335K | 9.37M | 9.63M | 5.69M | 177K | 3.25M | -6.3M | 2.05M |
| Cash from Investing | -7.61M | -50.5M | 1.78M | 35.62M | -35.87M | -54.34M | 7.28M | -2.76M | -15.51M | -102.63M |
| Capital Expenditures | -4.25M | -13.34M | -2.66M | -4.89M | -12.91M | -44.08M | -18.54M | -2.43M | -1.07M | -3.84M |
| CapEx % of Revenue | 0.08% | 0.31% | 0.11% | 0.38% | 0.85% | 0.86% | 0.61% | 0.13% | 1.42% | 0.09% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 14.21K | 321.82K | 7.16M | 1.26M | 369K | -13.15M | 10.96M | -456K | -14.44M | 0 |
| Cash from Financing | 217.35M | 460.64K | 41.27M | 236.49M | -3.86M | 27.32M | 47.52M | 1.15M | 82.86M | 89.8M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | -1K | 0 | 0 | 7.77M | -469K | -1.32M | 13.53M | 8.32M | -9.63M | -11.04M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -715.02K | -44.42M | -54.98M | -73.02M | -82.1M | -124.68M | -123.12M | -89.89M | -25.82M | 19.52M |
| FCF Margin % | -0.01% | -1.04% | -2.18% | -5.74% | -5.4% | -2.44% | -4.06% | -4.69% | -34.2% | 0.47% |
| FCF Growth % | -1.01% | -61.13% | -0.24% | -0.33% | -0.12% | -0.52% | 0.01% | 0.27% | 0.71% | 1.76% |
| FCF per Share | -0.02 | -1.24 | -1.54 | -1.79 | -1.93 | -2.93 | -2.75 | -1.97 | -0.45 | 0.22 |
| FCF Conversion (FCF/Net Income) | -0.16x | 0.49x | 0.53x | 0.87x | 0.68x | 0.99x | 0.92x | 0.82x | 0.24x | -0.60x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -12.46% | -22.74% | -35.49% | -21.38% | -25.34% | -24.41% | -41.88% | -58.57% | -95.96% | -34.08% |
| Return on Invested Capital (ROIC) | - | - | - | - | -442.28% | -29.31% | -47.6% | -51.02% | -100.68% | -79.56% |
| Gross Margin | 95.08% | 96.04% | 89.6% | 78.49% | 25% | 96.18% | 93.92% | 55.75% | -882.65% | 77.88% |
| Net Margin | -40.81% | -150.1% | -394.51% | -618.12% | -672.09% | -158.79% | -376.32% | -553.64% | -13385.3% | -88.57% |
| Debt / Equity | 0.01x | 0.01x | 0.00x | 0.00x | 0.13x | 0.35x | 0.43x | 0.60x | 1.00x | 0.70x |
| Interest Coverage | -1329.73x | -10136.33x | -165.45x | -145.35x | -41.75x | -3.51x | -23.69x | -23.68x | -18.33x | -7.99x |
| FCF Conversion | -0.16x | 0.49x | 0.53x | 0.87x | 0.68x | 0.99x | 0.92x | 0.82x | 0.24x | -0.60x |
| Revenue Growth | 109.3% | -22.63% | -40.85% | -49.46% | 19.32% | 236.12% | -40.56% | -36.83% | -96.06% | 5397.48% |
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Therapeutics | - | - | - | - | - | 25.73M | - |
| Therapeutics Growth | - | - | - | - | - | - | - |
| High Oleic Soyabean Oil | - | - | 1.7M | 22.9M | 27M | - | - |
| High Oleic Soyabean Oil Growth | - | - | - | 1247.06% | 17.90% | - | - |
| ALLO715 | - | - | 5M | 28.5M | - | - | - |
| ALLO715 Growth | - | - | - | 470.00% | - | - | - |
| High Oleic Soyabean Meal | - | - | 5.6M | - | - | - | - |
| High Oleic Soyabean Meal Growth | - | - | - | - | - | - | - |
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| FRANCE | 24.68M | 12.49M | 7.9M | 51.06M | 30.35M | 19.17M | 755K |
| FRANCE Growth | - | -49.37% | -36.81% | 546.62% | -40.56% | -36.83% | -96.06% |
| UNITED STATES | 508K | 236K | 7.29M | 22.89M | 26.95M | - | - |
| UNITED STATES Growth | - | -53.54% | 2990.68% | 213.85% | 17.71% | - | - |
Cellectis S.A. (CLLS) reported $75.3M in revenue for fiscal year 2024. This represents a 263% increase from $20.7M in 2011.
Cellectis S.A. (CLLS) grew revenue by 5397.5% over the past year. This is strong growth.
Cellectis S.A. (CLLS) reported a net loss of $35.4M for fiscal year 2024.
Cellectis S.A. (CLLS) has a return on equity (ROE) of -34.1%. Negative ROE indicates the company is unprofitable.
Cellectis S.A. (CLLS) had negative free cash flow of $32.7M in fiscal year 2024, likely due to heavy capital investments.